RAPP - Rapport Therapeutics, Inc. News

UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71

UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating a

Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Ta

Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating a

Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65

Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a B

Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade

Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and ant

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania

zacks.com

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and va

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the

Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP

Legal and General Group Plc acquired a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ: RA

Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (

Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP

Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) duri

Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP

Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) du

Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Time to Buy?

Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Cl

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“

Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise

Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 2

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the a

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling

Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86

Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rat

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

fool.com

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer

COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on

Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price

Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wi

Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“R

Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56

Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy ra

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

zacks.com

Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss

Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks

Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the ana

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seiz

Modalités de mise à disposition du rapport financier annuel 2025

MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CR

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the

Wells Fargo Maintains Overweight on Rapport Therapeutics, Raises Price Target to $46

Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweig

Rapport Therapeutics Files Shelf Registration To Offer Common Stock, Preferred Stock, Debt Securitie

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or mor

Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the a

Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures

Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,

This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mo

Wells Fargo Initiates Coverage On Rapport Therapeutics with Overweight Rating, Announces Price Targe

Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wit

Rapport Therapeutics Plans to Initiate Its Phase 3 Program for RAP-219 in Focal Onset Seizures in Q2

CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potentia

HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $40

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a

Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benef

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median re

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wedn

BTIG Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $47

BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rat

Citizens Maintains Market Outperform on Rapport Therapeutics, Raises Price Target to $80

Citizens analyst Jason N. Butler maintains Rapport Therapeutics (NASDAQ:RAPP) with a Market Outpe

Rapport Therapeutics Q3 EPS $(0.71) Beats $(0.77) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the ana